Larynx-preserving limited resection with total thoracic esophagectomy and gastric pull-up reconstruction: A promising treatment for selected cervical esophageal squamous cell carcinoma

Finally, the survival data showed that the median survival time was 31.83 months (95% CI=12.39-51.28 months) and the 3-year and 5-year survival rates were 49.1% and 35.5%, respectively.Conclusion: Larynx-preserving limited resection with total thoracic esophagectomy and gastric pull-up reconstruction might be a feasible and effective surgical alternative for the cervical ESCC patients whose tumor does not involve the larynx and hypopharynx.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Background/Aims: There is no consensus on treatment for cervical esophageal squamous cell carcinoma (ESCC).

📊

Key Findings & Data:Our aim is to evaluate the feasibility and outcome of larynx-preserving limited resection with total thoracic esophagectomy and gastric pull-up reconstruction for the treatment of cervical ESCC without tumor involvement of the larynx and hypopharynx.Materials and Methods: Retrospective analysis of patients with cervical ESCC who underwent R0 surgical resection from 2006 to 2011 in our center was performed.

💡

Conclusion & Impact:Finally, the survival data showed that the median survival time was 31.83 months (95% CI=12.39-51.28 months) and the 3-year and 5-year survival rates were 49.1% and 35.5%, respectively.Conclusion: Larynx-preserving limited resection with total thoracic esophagectomy and gastric pull-up reconstruction might be a feasible and effective surgical alternative for the cervical ESCC patients whose tumor does not involve the larynx and hypopharynx.

🔬Design:Research Article

📍Scope:2006 Verileri

⚙️Variables:Domain Parameters

Özet

Background/Aims: There is no consensus on treatment for cervical esophageal squamous cell carcinoma (ESCC). Our aim is to evaluate the feasibility and outcome of larynx-preserving limited resection with total thoracic esophagectomy and gastric pull-up reconstruction for the treatment of cervical ESCC without tumor involvement of the larynx and hypopharynx.Materials and Methods: Retrospective analysis of patients with cervical ESCC who underwent R0 surgical resection from 2006 to 2011 in our center was performed. Kaplan-Meier method was used to calculate the survival time for patients.Results: In total, 74 cervical ESCC patients were enrolled in the study. The mortality rate in 30 days was 8.1%, the total complication rate (at least one) was 47.3%, anastomosis leakage occurrence was 37.8%, mechanical ventilation ratewas12.2%, the rate of normal oral diet within 15 days was 71.6%, and the anastomosis recurrence rate in follow-up was 8.1%. Detailed analysis showed that the anastomosis leakage, pulmonary infection, laryngeal recurrent nerve injury, and chylothorax were the most common complications in surgical patients. Finally, the survival data showed that the median survival time was 31.83 months (95% CI=12.39-51.28 months) and the 3-year and 5-year survival rates were 49.1% and 35.5%, respectively.Conclusion: Larynx-preserving limited resection with total thoracic esophagectomy and gastric pull-up reconstruction might be a feasible and effective surgical alternative for the cervical ESCC patients whose tumor does not involve the larynx and hypopharynx.

🔖

Cite This Article

WANG, W., MA, J., LU, Q., HAN, Y., LI, X., JIANG, T., ZHAO, J. (2020). Larynx-preserving limited resection with total thoracic esophagectomy and gastric pull-up reconstruction: A promising treatment for selected cervical esophageal squamous cell carcinoma. Turkish Journal of Gastroenterology, Cilt: 31 - Sayı: 12, 948–954. https://ajindex.com/articles/410021

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (11)

Ozawa S, Tachimori Y, Baba H, et al. Comprehensive registry of esophageal cancer in Japan, 2003. Esophagus 2011; 8: 9-29
Yin WB, Zhang L, Miao Y, et al. The results of high energy electron therapy in carcinoma of the esophagus compared with telecobalt thera-py. Clin Radiol 1983; 34: 393-406
Grass GD, Cooper SL, Armeson K, Garrett-Mayer E, Sharma A. Cer-vical esophageal cancer: a population-based study. Head Neck 2015; 37: 808-14
Huang SH, Lockwood G, Brierley J, et al. Effect of concurrent high dose cisplatin chemotherapy and conformal radiotherapy on cervi cal esophageal cancer survival. Int J Radiat Oncol Biol Phys 2008; 71: 735-40
Ott K, Lordick F, Molls M, Bartels H, Biemer E, Siewert JR. Limit ed resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus. Br J Surg 2009; 96: 258-66
Daiko H, Hayashi R, Saikawa M, et al. Surgical management of carci-noma of the cervical esophagus. J Surg Oncol 2007; 96: 166- 72
Wang HW, Chu PY, Kuo KT, et al. A reappraisal of surgical man age-ment for squamous cell carcinoma in the pharyngoesophageal junction. J Surg Oncol 2006; 93: 468-76. 8.Miyata H, Yamasaki M, Takahashi T, et al. Larynx-preserving lim ited resection and free jejunal graft for carcinoma of the cervical esophagus. World J Surg 2013; 37: 551-7. 9.Chou SH, Li HP, Lee JY, Huang MF, Lee CH, Lee KW. Radical resec tion or chemoradiotherapy for cervical esophageal can-cer? World J Surg 2010; 34: 1832-9. 10.Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of lo cal-ly advanced esophageal cancer: long-term follow-up of a pro spective randomized trial (RTOG 85-01). Radiation Therapy Oncolo gy Group. JAMA 1999; 281: 1623-7. 11.Pignon JP, le Ma^ıtre A, Maillard E, Bourhis J, MACH-NC Collab ora-tive Group. Meta-analysis of chemotherapy in head and neck cancer (MACHNC):an update on 93 randomised trials and 17,346 patients. Ra-diother Oncol 2009; 92: 4-14
NCCN (2015). National comprehensive cancer network clinical prac-tice guidelines in oncology. National Comprehensive Cancer Network, Fort Washington
Tong DK, Law S, Kwong DL, et al. Current management of cervi cal esophageal cancer. World J Surg 2011; 35: 600-7
Wang S, Liao Z, Chen Y, et al. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a sin gle-institution experience. J Thorac Oncol 2006; 1: 252-9
Uno T, Isobe K, Kawakami H, et al. Concurrent chemoradiation for patient